Sign Out
It should not be given to patients with active liver disease. Liver function should be assessed before starting treatment and subsequently when clinically indicated; additional assessment after 3 months and before and after dosage increases has been advised for some statins, particularly when high doses are given.
It should be used with caution in patients with renal impairment as the risk of myopathy is increased.
It should be stopped if creatine phosphokinase increases significantly or if myopathy is diagnosed.
